Part 4/10:
In reaction to the news, Insight's stock took a significant hit, emphasizing the volatility inherent in biotech investments. Both hosts agreed that while the company still has a robust pipeline and a commercially successful drug, Jakafi, the reliance on post-hoc analyses following such a significant failure can often cloud future prospects.